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ABSTRACT
The role of specific immunoglobulins at mucosal sites in imparting protection against disease, such as ro-
tavirus-associated diarrhoea, is well-established. Oral immunoglobulin therapy with egg yolk-derived anti-
rotavirus immunoglobulins has previously been shown to achieve moderate therapeutic effect in diarrhoea 
due to rotavirus in a clinical trial. Here, data on the therapeutic potential of the same immunoglobulin 
preparation in an infant mouse model of rotavirus-induced diarrhoea is presented. The use of an animal 
model has allowed therapy to be evaluated with higher doses of immunoglobulins and has suggested that 
an improved therapeutic effect can be achieved by increasing the dose in the clinical setting.
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INTRODUCTION
Rotavirus, the leading aetiological agent of severe 
gastroenteritis in infants and young children, is an 
important public-health problem worldwide. It in-
fects about 90% of humans before three years of 
age, causing an estimated 125 million episodes of 
diarrhoea annually in children aged less than five 
years in developing countries (1). The high mortali-
ty and morbidity associated with rotavirus-associ-
ated gastroenteritis makes its treatment and pre-
vention an important public-health goal. However, 
specific, effective, and affordable therapy is cur-
rently not available. Two rotavirus vaccines—Ro-
tarix (Glaxo SmithKline Biologicals, Belgium) and 
RotaTeq (Merck & Co., USA)—have recently com-
pleted Phase III clinical trials. Both the vaccines 
were efficacious in preventing severe gastroenteri-
tis, predominantly due to the G1 rotavirus serotype 
(2). However, their use is limited to children aged 
less than three months, and confirmation of their 
safety will require extensive post-marketing sur-
veys and continuous epidemiological surveillance 
on circulating strains will be required wherever the 
vaccines are introduced. There is, thus, a clear need 
to define improved, cost-effective interventions in 
the management of diarrhoea due to rotavirus until 
the time an effective, safe, and inexpensive vaccine, 
affordable to developing countries, is available. 
Oral administration of virus-neutralizing specific 
antibodies is an attractive approach for passive pro-
tection of humans and animals against gastrointes-
tinal pathogens. We have documented the success-
ful treatment of rotavirus-associated diarrhoea in 
children with immunoglobulin from immunized 
cow colostrums with titres of 7,500 against sero-
type 1, 2,000 against serotype 2, 4,500 against sero-
type 3, and 4,500 against serotype 4 (3). In laying 
hens, immunoglobulin is transported to the yolk of 
eggs and provides passive immunity to the chicks. 
Eggs from hens immunized against different anti-
gens are, thus, a rich source for harvesting specific 
immunoglobulins (IgY). Purified IgY has previously 
been produced and used against a number of muco-
sal pathogens, including rotavirus. In a clinical trial 
by Sarker and colleagues that evaluated therapy of 
severe diarrhoea due to rotavirus using specific IgY, 
a modest beneficial effect of the treatment in re-
ducing stool output and achieving faster clearance 
from virus was observed (4). However, the main 
clinical outcome of disease, i.e. duration of diar-
rhoea, remained unchanged. Protection achieved 
by passive immunotherapy does not involve active 
participation of the host’s immune system but re-
flects solely the effect of extraneously-delivered im-Sarker SA et al. Chicken egg yolk immunoglobulin in rotavirus-associated diarrhoea
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munoglobulins. For a successful passive immuno-
therapy, there has to be enough immunoglobulins 
present at the mucosal site to control the infection 
process, a premise that is also supported in the ob-
served dose dependency of passive immunothera-
py in controlling infections (5).
Using immunoglobulins prophylactically results in 
an improved outcome since the infection can be 
easily stifled. However, prophylactic administra-
tion of immunoglobulins is usually not possible. To 
our knowledge, the clinical trial by Sarker and col-
leagues (4) was the first one and only therapeutic 
evaluation of IgY against rotavirus in humans. The 
titre of IgY in the final preparation was relatively 
low, and only 1.5 g of immunoglobulins (in 10 g 
of immunized egg yolk powder) could be given per 
day. Although the therapeutic efficacy of IgY in 
this trial was modest, using a small animal model 
of rotavirus-associated diarrhoea, we investigated 
whether an improved therapeutic effect could be 
achieved using higher doses of IgY.
MATERIALS AND METHODS
Anti-rotavirus IgY immunoglobulins
The egg yolk immunoglobulin was obtained from 
Nutritional Foods Division, Taiyo Kagaku Co., Ltd., 
Yokkaichi, Japan. The production of hyperimmu-
nized egg yolk (HEY) immunoglobulin has been 
described previously by Hatta et al. (6,7). In brief, 
white leghorn hens, aged 150 days, were immu-
nized intramuscularly with 1x107 fluorescent cell-
forming units (FCFUs) of human rotavirus strains—
Wa, RV5, RV3, and ST3—twice at an interval of one 
week using Freund’s complete adjuvant. After the 
initial immunization, eggs were collected daily and 
stored in the cold temperature for two weeks. Then, 
their yolks were separated, pooled, and frozen for 
purification of IgY. The purification of HEY from 
pooled eggs, collected 4 to 22 weeks after immuni-
zation, was in accordance with the procedures de-
scribed by Hatta et al. (6,7) and Polson et al. (8). The 
neutralization titre, measured in a neutralization 
test against serotype 3, was 1:100,000 (9). The pro-
tein content of the preparations was 68.7%, with 
an IgY content of 20%.
Animal experiments
Fourteen-day pregnant, rotavirus-negative Balb/c 
mice were obtained from Taconic Labs, Denmark. 
The mice were housed individually in the animal 
facility at Huddinge Hospital, Stockholm, Sweden. 
Normal pellet diet and water was provided ad libi-
tum. The Animal Ethics Committee of Karolinska 
University Hospital at Huddinge, Stockholm, ap-
proved the study. Pups were born on day 19-20 of 
gestation, and four-day old pups were randomized 
to different experimental groups. Pups were orally 
challenged with 2x107 foci-forming units (FFUs) of 
rhesus rotavirus (strain RRV) in a 10-µl volume on 
day 0 of experiment. Feeding with anti-rotavirus 
IgY in a total volume of 10 µl phosphate-buffered 
saline commenced from day 1 to day 5. Four differ-
ent doses of IgY were tested: 10 mg/mL (n=15), 1 
mg/mL (n=15), 0.1 mg/mL (n=11), and 0.01 mg/mL 
(n=7). The control group (n=15) included pups that 
were only infected. The pups were checked daily 
for signs of diarrhoea, which included loose stools 
on gentle palpation of the abdomen or a smeared 
tail during the six days of the experiment. The out-
come measures were prevalence of diarrhoea (de-
fined as the percentage of pups with diarrhoea on 
a daily basis) and duration of diarrhoea (defined as 
time in days with diarrhoea). 
Statistics
The chi-squared test (Epi Info software, version 
3.4, 2005) was used for comparing the propor-
tion of pups with diarrhoea following RRV chal-
lenge and treatment with different concentrations 
of IgY. The duration of diarrhoea among the pups 
with  different  interventions  was  compared  with 
one-way analysis of variance (ANOVA), and that 
between two groups was compared by the Student’s 
t-test (SPSS software, version 10 Windows). 
RESULTS
Oral inoculation of RRV typically induced diar-
rhoea 24 hours post-inoculation with the disease 
peaking around day 3 to day 4. A positive outcome 
of therapeutic feeding with IgY and a clear dose de-
pendency could be observed. Four different doses of 
IgY were tested from 0.01 mg/mL up to 10 mg/mL. 
Feeding higher doses of IgY (1 mg/mL) had a stron-
ger effect on the prevalence of diarrhoea on day 4 
(33% vs 67% for control, p=0.006). The beneficial 
effect was more pronounced in pups receiving the 
10-mg/mL dose on day 4 (6% vs 67% for control, 
p=0.0006). Feeding lower doses resulted in no sig-
nificant effect on the prevalence of diarrhoea (63% 
for 0.1 mg/mL and 86 % for 0.01 mg/mL compared 
to 67% for controls, p=NS) (Table 1).
The duration of diarrhoea was also reduced with 
treatment with IgY and showed a dose-dependent 
behaviour. Lower doses with 0.01 mg/mL and 0.1 
mg/mL resulted in significant reduction or slight Sarker SA et al. Chicken egg yolk immunoglobulin in rotavirus-associated diarrhoea
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effect on duration of diarrhoea compared to the 
control. On the contrary, larger doses elicited 
significant relative reduction in duration of di-
arrhoea compared to the control mice or even 
mice receiving lower amounts of IgY (F=6.7, 
p=<0.0001). Treatment with the 10-mg/mL dose 
achieved the strongest reduction compared to 
the control mice or even mice receiving lower 
amounts of IgY (69% vs 17% for 0.1 mg/mL, 31% 
for 0.01 mg/mL) (Table 2). 
DISCUSSION
In this study, we have used a well-characterized 
standard rotavirus infection model in Balb/c mice 
previously described by Ruggeri and co-workers 
(10). Oral inoculation with RRV induces typical 
signs of rotavirus-associated diarrhoea with loose 
stools and associated histopathological changes 
(Pant N. Personal communication, 2006). We have 
recently used this animal model for testing a yeast-
produced, monovalent, llama antibody fragment 
against rotavirus (11). Here, we have evaluated the 
therapeutic potential of anti-rotavirus IgY. Chicken 
IgY is homologous to the mammalian IgG and is 
associated with transferring passive immunity to 
the maturing egg. Hens can readily be hyperimmu-
nized, and the concentration of IgY in the egg yolk 
can be as high as 25 mg/mL (12), making IgY a very 
attractive source of passive immunization. With 
reference to rotavirus, IgY has been used experi-
mentally in mice (5,13,14) and calves (15). How-
ever, these studies have only evaluated the effect 
of prophylactic administration of IgY. Prophylactic 
administration of immunoglobulins represents 
an ideal situation where, owing to the presence of 
immunoglobulins even before the pathogen is in-
troduced, the protection is immediate. Although 
Table 2. Reduction in duration of rotavirus-induced diarrhoea in mouse pups after oral 
administration of different concentration of anti-rotavirus IgY*
Treatment group
Duration 
of diarrhoea  
(days)
% of relative reduc-
tion compared to 
control
F value p value
IgY 10 mg/mL (n=15)† 0.9±1.0 69
6.7 <0.0001
IgY 1 mg/mL (n=15)‡ 1.7±1.2 41
IgY 0.1 mg/mL (n=11)§ 2.4±1.3 17
IgY 0.01 mg/mL (n=7)§ 2.0±1.2 31
RRV (control) (n=15) 2.9±1.2 -
*One way analysis of variance (ANOVA); †p values are significant with all groups; ‡p value 
is significant with control only; §p value is not significant with control
Table 1. Therapeutic effect of different doses of orally-administered IgY against RRV- 
induced diarrhoea in infant mice
Treatment group
Day 1 Day 2 Day 3 Day 4
No. (%) with 
diarrhoea
 No. (%) with 
diarrhoea
No. (%) with 
diarrhoea
No. (%) with 
diarrhoea
IgY 10 mg/mL (n=15) 3 (20) 5 (33) 4 (27) 1 (6)
IgY 1 mg/mL (n=15) 4 (27) 7 (47) 6 (40) 5 (33)
IgY 0.1 mg/mL (n=11) 2 (18) 5 (45) 7 (63) 7 (63)
IgY 0.01 mg/mL (n=7) 0 5 (71) 3 (43) 6 (86)
RRV (control) (n=15) 8 (53) 13 (87) 12 (80) 10 (67)
IgY 10 mg/mL vs control:  Day 1: χ2=3.6, p=0.06, RR 0.12 (95% CI 0.38-1.15); Day 2: χ2=8.9, p=0.003, RR 
0.38 (95% CI 0.18-0.81); Day 3: χ2=8.6, p=0.003, RR 0.50 (95% CI 0.39-0.65); Day 
4: χ2=11.6, p=0.0006, RR 0.10 (95% CI 0.1-0.69) 
IgY 1 mg /mL vs control:  Day 1: χ2=2.2, p=0.13, RR 0.05 (95% CI 0.32-1.85); Day 2: χ2=5.4, p=0.020, RR 
0.54 (95% CI 0.30-0.96); Day 3: χ2=5.0, p=0.025, RR 0.50 (95% CI 0.26-0.98); Day 
4: χ2=3.3, p=0.06, RR 0.50 (95% CI 0.22-1.1)
CI=Confidence interval; IgY=Yolk immunoglobulin; RR=Relative risk; RRV=Rhesus rotavirusSarker SA et al. Chicken egg yolk immunoglobulin in rotavirus-associated diarrhoea
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administering immunoglobulins prophylactically 
may shed some light on their potential clinical 
use, it seldom represents the real-life scenario. We 
have, therefore, evaluated therapeutic intervention 
using four different doses of IgY after challenging 
mice with rotavirus. Results from our current study 
demonstrate that therapy with IgY is clearly dose-
dependent with the highest dose of 10 mg/mL im-
parting the strongest protection at least in mouse 
pups. As originally designed, we have not fixed the 
dose according to that used in the clinical study 
(4) or according to body-weight. The doses used in 
this study were arbitrarily chosen beginning from 
a lower to a higher dose to test the hypothesis that 
an improved therapeutic effect could be achieved 
using higher doses of IgY in mice and then extrapo-
lating/hypothesing that more would probably have 
been better to have used more in the human study 
as well, since we got rather poor clinical results.
We have previously conducted a randomized dou-
ble-blind clinical trial testing the therapeutic abili-
ty of IgY in patients with severe diarrhoea due to 
rotavirus (4). In this study, we had used a standard 
dose of 1.5 g IgY (in 10 g of immunized egg yolk 
powder) per day for four days. Treatment with IgY 
caused a faster clearance of virus shedding but did 
not reduce the duration of the disease. Presumably, 
at the time the patients were admitted to the trial, 
they had the peak of infection with high levels of 
rotavirus particles. Based on our current results, it 
is likely that using higher doses of IgY, or a prod-
uct with a higher titre for treatment, would have 
given a better outcome in the previous clinical trial 
and should be considered in designing such trials 
in future.
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